Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hepatitis B, Chronic Patients who, in the opinion of the investigator, can and will comply with the requirements of the protocol Written informed consent obtained from the patient prior to performing any study specific procedure A male or female between, and including, 18 and 65 years of age at the time of the first vaccination Female patients of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral ovariectomy or post-menopause Female patients of childbearing potential may be enrolled in the study if the patient has practiced adequate contraception for 30 days prior to vaccination, and has a negative pregnancy test at Screening, and has agreed to continue adequate contraception from Screening until 12 weeks after completion of the vaccination series Male patients with documented bilateral vasectomy and resultant azoospermia, bilateral orchiectomy or azoospermia, or  Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day -29 to Day 1), or planned use during the study period Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe Chronic administration of immunosuppressants (defined as more than 14 days in total) or other immune-modifying drugs (including but not limited to IFN) during the period starting six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 10 mg/day or equivalent. Inhaled and topical steroids are allowed Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period Use of systemic cytotoxic agents, chronic antiviral agents or Chinese herbal medicines which, in the opinion of the investigator, may have activity against HBV within the previous 6 months prior to randomization into this study. Antiviral treatment/prevention for influenza or herpes simplex virus (HSV) is allowed Administration of adenovirus/adenovector-based or MVA-based vaccine within the last 12 months Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 14 days before each dose and ending 30 days after each dose of vaccines, with the exception of influenza vaccine that may be given at any time except within a 7-day period before or after each vaccine dose Treatment with nephrotoxic drugs or competitors of renal excretion within 2 months prior to Screening or the expectation that patient will receive any of these during the course of the study. TAF/TDF given as NA therapy is allowed Concurrently participating in another clinical study, at any time during the study period, in which the patient has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device) Medical history of cirrhosis